Lipotoxicity-Related Hematological Disorders in Obesity.

about

Lipotoxicity-Related Hematological Disorders in Obesity.

Item

http://www.wikidata.org/entity/Q39353771

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Lipotoxicity-Related Hematological Disorders in Obesity.

@en

Lipotoxicity-Related Hematological Disorders in Obesity.

@nl

type

Item

label

Lipotoxicity-Related Hematological Disorders in Obesity.

@en

Lipotoxicity-Related Hematological Disorders in Obesity.

@nl

prefLabel

Lipotoxicity-Related Hematological Disorders in Obesity.

@en

Lipotoxicity-Related Hematological Disorders in Obesity.

@nl

P1476

Lipotoxicity-Related Hematological Disorders in Obesity.

@en

P2093

Ibrahim Celalettin Haznedaroglu

http://www.w3.org/2001/XMLSchema#string

Umit Yavuz Malkan

http://www.w3.org/2001/XMLSchema#string

P2860

Role of lipotoxicity in endothelial dysfunction

Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo

Identification of two subtypes in the rat type I angiotensin II receptor

Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells

Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction.

Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders

Genetic variants of the Renin Angiotensin system: effects on atherosclerosis in experimental models and humans.

Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II.

Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis

Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.

P304

469-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/978-3-319-48382-5_20

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

960

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28585212

http://www.w3.org/2001/XMLSchema#string